Differential effects of mitochondrial inhibitors on porcine granulosa cells and oocytes.

Oocytes and granulosa cells rely primarily on mitochondrial respiration and glycolysis for energy production, respectively. The present study examined the effect of mitochondrial inhibitors on the ATP contents of oocytes and granulosa cells. Cumulus cell-oocyte complexes (COCs) and granulosa cells (GCs) were collected from the antral follicles of porcine ovaries. Treatment of denuded oocytes with either carbonyl cyanide m-chlorophenyl hydrazine (CCCP), antimycin, or oligomycin significantly reduced ATP content to very low levels (CCCP, 0.12 pM; antimycin, 0.07 pM; and oligomycin, 0.25 pM; P < 0.05), whereas treatment with a glycolysis inhibitor (bromopyruvic acid, BA) had no effect. Conversely, the ATP content of granulosa cells was significantly reduced by treatment with the glycolysis inhibitor but was not affected by the mitochondrial inhibitors (ATP/10,000 cells; control, 1.78 pM and BA, 0.32 pM; P < 0.05). Reactive oxygen species (ROS) generation after CCCP treatment was greater in oocytes (1.6-fold) than that seen in granulosa cells (1.08-fold). Oocytes surrounded by granulosa cells had higher ATP levels than denuded oocytes. Treatment of COCs with CCCP reduced, but did not completely abolish, ATP content in oocytes (control, 3.15 pM and CCCP, 0.52 pM; P < 0.05), whereas treatment with CCCP plus a gap junction inhibitor, 18α-glycyrrhetinic acid, and CCCP decreased the ATP content to even lower levels (0.29 pM; P < 0.05). These results suggest that granulosa cells are dependent on glycolysis and provide energy to oocytes through gap junctions, even after treatment with CCCP.

A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.

Lipodystrophy is a rare disorder characterized by complete or partial loss of adipose tissue. Patients with lipodystrophy exhibit hypertriglyceridemia, severe insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Efforts to ameliorate NASH in lipodystrophies with pharmacologic agents have met with limited success. We examined whether a controlled-release mitochondrial protonophore (CRMP) that produces mild liver-targeted mitochondrial uncoupling could decrease hypertriglyceridemia and reverse NASH and diabetes in a mouse model (fatless AZIP/F-1 mice) of severe lipodystrophy and diabetes. After 4 wk of oral CRMP (2 mg/kg body weight per day) or vehicle treatment, mice underwent hyperinsulinemic-euglycemic clamps combined with radiolabeled glucose to assess liver and muscle insulin responsiveness and tissue lipid measurements. CRMP treatment reversed hypertriglyceridemia and insulin resistance in liver and skeletal muscle. Reversal of insulin resistance could be attributed to reductions in diacylglycerol content and reduced PKC-ε and PKC-θ activity in liver and muscle respectively. CRMP treatment also reversed NASH as reflected by reductions in plasma aspartate aminotransferase and alanine aminotransferase concentrations; hepatic steatosis; and hepatic expression of IL-1α, -ß, -2, -4, -6, -10, -12, CD69, and caspase 3 and attenuated activation of the IRE-1α branch of the unfolded protein response. Taken together, these results provide proof of concept for the development of liver-targeted mitochondrial uncoupling agents as a potential novel therapy for lipodystrophy-associated hypertriglyceridemia, NASH and diabetes.-Abulizi, A., Perry, R. J., Camporez, J. P. G., Jurczak, M. J., Petersen, K. F., Aspichueta, P., Shulman, G. I. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.

Meta-analysis of the effects of laidlomycin propionate, fed alone or in combination with chlortetracycline, compared with monensin sodium, fed alone or in combination with tylosin, on growth performance, health, and carcass outcomes in finishing steers in North America.

The objective of this research was to use data from multiple studies to comprehensively quantify the effects of feeding 1) laidlomycin propionate (LP), alone and/or in combination with chlortetracycline, compared with 2) monensin sodium (MS), alone and/or in combination with tylosin, at commercially approved dosages, on ADG, DMI, feed efficiency (FE), mortality, and carcass characteristics (HCW and liver abscesses). A secondary objective was to explore potential sources of heterogeneity among the comparative effectiveness studies. A systematic review of peer-reviewed literature and industry reports was used to identify studies that included direct comparisons of these treatments in finishing steers in North America. Random-effects meta-analysis models of performance, carcass, and health-related outcomes were fitted with extracted data, consisting of a total of 17 data sets comprising a total of 135 pens and 13,603 steers. Results showed that pens of steers fed LP had increased ADG (live and carcass adjusted), DMI, and HCW compared with those fed monensin ( < 0.05). However, liver abscesses were more common in LP-fed cattle than in MS-fed cattle ( < 0.05), presumably because of differences in the concurrently fed antimicrobials. No significant effects ( > 0.05) were identified for FE or for health-related outcomes (overall and cause-specific mortality). There was a substantial amount of heterogeneity in outcomes among studies, and when pen size and type of production setting were included in mixed-effects meta-regression models, they accounted for only a small proportion of the between-study heterogeneity found in the meta-analysis models. Therefore, caution should be exercised when interpreting summary estimates in the presence of substantial heterogeneity. However, these results provide comprehensive information on the comparative effects of different ionophores across multiple studies and multiple years, states, and production settings. These unique results can enable quantitative and informed decisions by potential end users of these feed additives that are widely used in the U.S. beef industry for reducing the costs of beef production through enhanced cattle performance.

Comparison of feed additive technologies for preconditioning of weaned beef calves.

Our objective was to evaluate the response of weaned calves to different supplemental feed additives in a supplement to affect calf performance and mitigate stress response observed during weaning and preconditioning. At weaning in each of 2 yr, 160 Angus and Brangus calves (203 and 227 ± 2.3 and 2.5 kg) were stratified by BW, sex, and breed and were randomly allotted to 1 of 4 treatments ( = 40 calves/treatment): 1) supplement without feed additives (control, CON), 2) supplemented with chlortetracycline, 350 mg/d (CTC), 3) supplemented with monensin, 175 mg/d (RUM), and 4) supplemented with rumen modifier, 5 g/d (ACT). Calves were held by treatment in 1 of 4 drylot pens for 7 d after weaning and were offered ad libitum access to hay and 2.27 kg/d of supplement before placement in one of thirty-two 0.8-ha pastures (5 calves/pasture). On pasture calves were supplemented with 2.27 kg/d (yr 1) or supplemented at 1.0% BW (yr 2). Calf BW and blood samples were collected following weaning (d 0, 1, 4, 7, 11 in yr 1; d 0, 1, 3, 7, 14 in yr 2), at the conclusion of the preconditioning period (d 50, 51 in yr 2), and after transportation (d 52, 55, 59, 65 in yr 2) for analysis of acute phase protein (APP) concentrations. In yr 2, after 44 d on pasture, calves were loaded on 2 semitrucks and transported for 24 h. On return, calves were placed in 4 pastures with hay and fed their respective supplements for 14 d. For each year, data were analyzed with the MIXED procedure of SAS. The model included the main effect of treatment, and pasture was the experimental unit. All variables quantified by day were analyzed using repeated measures. In yr 1, ACT and CTC had greater (P <0.05) 52-d ADG than RUM, whereas CON was intermediate. However, in yr 2, over the 50-d postweaning period there was no difference (P = 0.20; 0.52 kg/d) in ADG response among treatments. After transportation, 7- and 14-d ADG were improved (P < 0.05) for ACT and CTC compared with CON and RUM. In both years, postweaning plasma concentrations of haptoglobin were similar (P > 0.05) among treatments; however an effect of day after transport (P < 0.001) was observed. Feed cost of gain and income over production cost (P ≥ 0.15; mean = $0.51/kg and $73.51, respectively) were not different among treatments. Use of supplemental additives may improve calf performance during a preconditioning period of this duration, but no additive was effective at mitigating stress postweaning. Additives were equally effective in supporting calf growth performance during a posttransportation period.

The effects of technology use in feedlot production systems on feedlot performance and carcass characteristics.

The objectives of this study were to examine the effects of feedlot production systems with and without the use of a ß-adrenergic agonist compared to an all-natural production program on feedlot performance and carcass characteristics. Crossbred beef steers ( = 336; initial BW = 379 ± 8 kg) were randomized to 1 of 3 treatments in a randomized complete block design (RCBD; 14 steers/pen; 8 pens/treatment). Treatments consisted of an all-natural treatment (NAT), a conventional treatment (CONV), and a conventional treatment with a ß-agonist (CONV-Z). All treatments were fed the same basal diet with NAT cattle receiving no growth promoting technologies. The CONV and CONV-Z cattle were implanted with 40 mg of estradiol and 200 mg of trenbolone acetate (TBA) on d 0 and were fed 33 and 9 mg/kg of monensin and tylosin daily, respectively. The CONV-Z cattle were fed zilpaterol hydrochloride (ZH) at 6.76 mg/kg (90% DM basis) for the last 20 days on feed (DOF) There was no effect of treatment on DMI ( = 0.83); however, CONV-Z steers gained 3.8% faster (1.64 vs. 1.58 kg/d; < 0.01) and were 5.3% more efficient (0.160 vs. 0.152; < 0.01) than CONV steers, and CONV steers gained 32.8% faster (1.58 vs. 1.19 kg/d; < 0.01) and were 26.7% more efficient (0.152 vs. 0.120; < 0.01) than NAT steers. There was a 35.7% improvement in estimated carcass gain (1.29 vs. 0.95 kg/d; < 0.01) and a 32.6% improvement in carcass efficiency (0.126 vs. 0.095; < 0.01) for CONV-Z steers compared to NAT steers. Hot carcass weight was increased by 8 kg for CONV-Z steers compared to CONV steers (394 vs. 386 kg; = 0.05) and 46 kg compared to NAT steers (394 vs. 348 kg; < 0.01). Longissimus muscle area was increased by 3.6 cm for CONV-Z steers compared to CONV steers (92.29 vs. 88.67 cm; = 0.02) and 12.1 cm for CONV-Z steers compared to NAT steers (92.29 vs. 80.16 cm; < 0.01), resulting in a 9.6% unit increase in USDA yield grade (YG) 1 (15.14 vs. 5.52%; < 0.05) and a 21.6% unit reduction in USDA YG 3 for CONV-Z steers compared to CONV steers (30.70 vs. 52.32%; < 0.05). The CONV-Z steers had a lower marbling score compared to the other treatments (432; 0.01), resulting in an 11.7% unit increase (20.70 vs. 9.03%; < 0.05) in USDA Select carcasses compared to CONV steers. The results of this experiment show that CONV-Z and CONV production results in a significant improvement in feedlot performance and USDA YG compared to NAT.

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.

Nonalcoholic fatty liver disease (NAFLD) is a major factor in the pathogenesis of type 2 diabetes (T2D) and nonalcoholic steatohepatitis (NASH). The mitochondrial protonophore 2,4 dinitrophenol (DNP) has beneficial effects on NAFLD, insulin resistance, and obesity in preclinical models but is too toxic for clinical use. We developed a controlled-release oral formulation of DNP, called CRMP (controlled-release mitochondrial protonophore), that produces mild hepatic mitochondrial uncoupling. In rat models, CRMP reduced hypertriglyceridemia, insulin resistance, hepatic steatosis, and diabetes. It also normalized plasma transaminase concentrations, ameliorated liver fibrosis, and improved hepatic protein synthetic function in a methionine/choline-deficient rat model of NASH. Chronic treatment with CRMP was not associated with any systemic toxicity. These data offer proof of concept that mild hepatic mitochondrial uncoupling may be a safe and effective therapy for the related epidemics of metabolic syndrome, T2D, and NASH.

Efficacy of controlled-release capsules containing monensin for the prevention of subclinical ketosis in pasture-fed dairy cows.

AIMS: To determine the effectiveness of intra-rumenal controlled release capsules (CRC) containing 32 g of monensin administered pre-calving to reduce the cumulative incidence of subclinical ketosis (SCK) in mainly pasture-fed dairy cows. METHODS: Cows (n=837) due to calve in the first 6 weeks of the spring calving period were enrolled from four commercial herds in the Waikato region of New Zealand in a blinded, randomised, negative-controlled field trial. Three weeks before the start of the calving period cows were randomly allocated to receive either no treatment (control) or a single CRC containing monensin and then blood sampled on two occasions, 7 days apart within 12 days following calving for measurement of concentrations of beta hydroxybutyrate (BHBA) in blood. Cows were diagnosed with SCK if the concentration of BHBA in blood in either of these samples was ≥1.2 mmol/L. RESULTS: Fewer treated cows were diagnosed with SCK within 12 days post-calving than control cows (144/340 (42.4%) vs. 192/336 (57.1%); p<0.001). There was no interaction between treatment group and age, breed or herd of origin. From the final multivariable model it was estimated that treatment with CRC containing monensin reduced the absolute cumulative incidence of SCK by 17.9 (95% CI=9.2-25.8)% compared to no treatment. CONCLUSIONS: Treatment with a CRC containing monensin>10 days prior to calving reduced the cumulative incidence of SCK of pasture-based dairy cows in commercial dairy herds within 12 days post-calving. CLINICAL RELEVANCE: Administration pre-calving of an intra-rumenal bolus containing monensin can be considered as one of a range of management options for the control of SCK in early lactation.

Effects of increasing levels of corn dried distillers grains with solubles and monensin on intake, digestion, and ruminal fermentation in beef heifers fed high-barley grain diets.

The objective of this study was to determine whether increasing corn-based dried distillers grains with solubles (DDGS) in high-barley grain diets reduces the merit of using higher levels of monensin by assessing intake, digestibility, and ruminal pH and fermentation in feedlot heifers. Five ruminally and duodenally cannulated Angus heifers (average BW of 599±36 kg) were used in a 5×5 Latin square with a 2×2+1 factorial arrangement. Treatments were control (CON, 10% barley silage, 90% barley-based concentrate, and 28 mg monensin/kg DM) and diets substituting 20% (LDG) or 40% (HDG) DDGS for barley grain with 28 mg (ML) or 48 mg (MH) monensin/kg diet DM: 1) CONML, 2) LDGML, 3) HDGML, 4) LDGMH, and 5) HDGMH. Contrasts compared LDG vs. HDG, ML vs. MH, interactions between DDGS and monensin, and the effect of increasing DDGS in the diet. Increasing DDGS quadratically (P<0.01) increased DMI. There was no interaction for DMI between the dietary inclusion rate of DDGS and the dose of monensin; however, DMI was reduced (P<0.05) for heifers fed MH vs. ML. Ruminal digestibility of OM, NDF, and starch linearly decreased (P<0.01), but intestinal digestibility linearly increased (P<0.01) with increasing DDGS, resulting in no differences in total tract digestibility. Ruminal digestibility of OM was greater (P<0.04) in heifers fed MH than ML; however, the total tract digestibility of OM was not affected. Intake of N, flows of total N, nonammonia N, and dietary N were linearly (P<0.02) increased, and the efficiency of ruminal microbial synthesis linearly (P<0.04) improved with increasing DDGS. Increasing DDGS inclusion linearly decreased (P<0.04) the acetate to propionate ratio. Inclusion of MH decreased (P<0.04) acetate and increased (P<0.05) NH3-N compared to ML, but high monensin did not affect mean ruminal pH, the duration of pH<5.8, 5.5, 5.2, or the area below the curve at pH 5.8, 5.5, and 5.2, indicating that there was no evidence that it modulated ruminal pH. These results suggest that feeding monensin at 48 vs. 28 mg/kg diet DM altered nutrient availability and site of feed digestion, likely as a result of reduced DMI and increased ruminal digestion of DM. High levels of monensin may reduce the risk of acidosis through a reduction in DMI, but in the present study this was not evident in differences in the ruminal pH profiles between heifers fed ML and MH diets.

Quantifying the effect of monensin dose on the rumen volatile fatty acid profile in high-grain-fed beef cattle.

Monensin is a common feed additive used in various countries, where 1 of the associated benefits for use in beef cattle is improved efficiency of energy metabolism by the rumen bacteria, the animal, or both. Modeling fermentation-altering supplements is of interest, and thus, it is the purpose of this paper to quantify the change in VFA profile caused by monensin dose in high-grain-fed beef cattle. The developmental database used for meta-analysis included 58 treatment means from 16 studies from the published literature, and the proportional change in molar acetate, propionate, and butyrate (mol/100 mol) as well as total VFA (mM) with monensin feeding dose (mg/kg DM, concentration in the feed) was evaluated using the MIXED procedure (SAS Inst. Inc., Cary, NC) with the study treated as a random effect. The mean monensin dose in the literature database was 30.9 ± 3.70 mg/kg DM and ranged from 0.0 to 88.0 mg/kg DM. Mean DMI was 7.8 ± 0.26 kg DM/d, mean concentrate proportion of the diet was 0.87 ± 0.01, and mean treatment period was 42 ± 5.6 d. Results produced the following equations: proportional change in acetate (mol/100 mol) = -0.0634 (± 0.0323) × monensin (mg/kg DM)/100 (P = 0.068), proportional change in propionate (mol/100 mol) = 0.260 (± 0.0735) × monensin (mg/kg DM)/100 (P = 0.003), and proportional change in butyrate (mol/100 mol) = -0.335 (± 0.0916) × monensin (mg/kg DM)/100 (P = 0.002). The change in total VFA was not significantly related to monensin dose (P = 0.93). The results presented here indicate that the shift in VFA profile may be dose dependent, with increasing propionate and decreasing acetate and butyrate proportions (mol/100 mol). These equations could be applied within mechanistic models of rumen fermentation to represent the effect of monensin dose on the VFA profile in high-grain-fed beef cattle.

Overview of meta-analysis of monensin in dairy cattle.

Monensin is an ionophore widely used in the dairy cattle industry throughout the world. A large volume of clinical trials have been conducted that have explored efficacy for various metabolic, production, and health outcomes. However, the results of the individual studies have in some cases been contradictory and in others inadequately sized to fully address the objectives particularly for health and production. The meta-analysis of monensin dairy data illustrates an example of the power of this tool for helping to make evidence-based decisions for health management and production consultants. Its importance and utility will continue to grow in future years.